The Perils Of A Pre-Filled Syringe: Device Issues Delayed Tbo-filgrastim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Choosing an established, off-the-shelf pre-filled syringe as the device to deliver its granulocyte colony-stimulating factor tbo-filgrastim proved no safeguard to Teva during FDA‘s meticulous review of the BLA.
You may also be interested in...
Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Complexity Has Benefits: Data Show Biologics, Targeted Agents Have Better Approval Prospects
Biologics have 9.1% likelihood of making it through the clinic to approval, compared to 5.7% for new molecular entities, according to an analysis of 10 years of Biomedtracker drug development data by BIO, Informa Pharma Intelligence and QLS.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: